Dublin, Nov. 16, 2022 (GLOBE NEWSWIRE) -- The "U.S. Gene Editing Market - Industry Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The U.S. gene editing market is expected to grow at a CAGR of 21.13% during 2022-2027.
MARKET INSIGHTS
Growth in the gene editing market is fueled by increasing demand for synthetic genes in the U.S. Genomics can be used to identify genetic abnormalities in humans, drug discovery, agriculture, veterinary medicine, and forensics. Gene editing requires tools and techniques that make unique changes to the DNA sequence of an organism's genes, fundamentally altering the genetic blueprint. Unlike genetic engineering, which randomly incorporates genetic material into the host genome, gene editing aims to make changes at specific target locations.
Genome editing technology is a technique for target gene modification that allows the knockout and addition of specific fragments of DNA. This technique is widely used in biomedical research, clinics, and agriculture. A growing preference for personalized medicine, rare disease treatment research, rising R&D spending and growth in the pharmaceutical and biotech industries, rapid advances in sequencing and genome editing technologies, and increasing use of products derived from genetically modified organisms. These are some of the factors that are boosting the growth of the U.S. gene editing market.
MARKET TRENDS AND OPPORTUNITIES
The Emergence of Novel Gene Editing Tools
- CRISPR changes the way scientists work on gene editing, providing unprecedented accuracy. However, CRISPR technology is not certain and has limitations that make the leap from gene therapy and cell therapy laboratories to the bedside
- Base editing is an innovative technology that can create gene knockouts and correct specific errors and mutations in the DNA of whole cells. Single nucleotide polymorphisms are highly pathogenic mutations that cause human illness and require only a single nucleotide change to correct the mutation
Increasing Pharma/Biotech, Venture Capital, & Government Funding for Gene Editing Projects
- Genome editing aims to modify the DNA sequence so cells can make the correct protein again. NIH created the SCGE program in January 2018 to improve genome editing technology and make genome editing therapies more widely available. Genome editing has a great potential to change the treatment environment for both common and rare diseases. Gene editing is in its infancy, and these newly funded projects promise better strategies to address various challenges, including the right genes in the genome. Over the past decade, the U.S. gene editing market is witnessing many new investments from governments, private equities, and venture capitalists.
- The most exciting developments in CRISPR therapeutics often come from start-ups. However, CRISPR treatments are also attracting interest from big pharmaceutical companies. Start-ups and big pharma often choose to partner. Some examples of small/large partnerships include Beam Therapeutics-Pfizer & Metagenomi-Moderna.
Diversified Application Areas of Gene Editing
- Genome editing is widely used in studying a wide variety of organisms. For example, CRISPR creates 'knockout' models of various animal diseases, allowing researchers to study the underlying genetic cause. It also modifies the genes of specific tissues and organs, focusing on the criminal's genes to facilitate disease research, creating disease cell models like human pluripotent stem cells, and creating pig organs
- Several technologies, including zinc finger endonucleases (ZFNs), transcriptional activator-like effector nucleases (TALENs), and clustered, regularly spaced, short-interval palindrome repeat/CRISPR-related nucleases (CRISPR/Cas) systems are used to achieve gene editing. Due to its simple design, rapid implementation, low cost, and robust scalability, researchers see the CRISPR/Cas system as an innovative gene-editing toolbox that extends to almost any genome target. This system is widely used, especially in cancer research, and is a potential approach for diagnosing and treating cancer
SEGMENTATIONS
Segmentation by Products
- Reagents & Consumables
- Equipment & Software
- Services
Segmentation by Technology
- CRISPER
- TALEN
- ZFN
- Others
Segmentation by Application
- Drug Discovery & Development (DDD)
- Animal Gene Editing
- Plant Gene Editing
- Others
Segmentation by End User
- Pharma & Biotech Companies (PBC)
- Academic & Research Institutes (ARI)
- Animal & Plant Biotech Companies (APBC)
- CROs/CDMOs
Key Vendors
- Agilent Technologies
- Creative Biogene
- Genscript
- Merck KGaA
- Thermo Fisher Scientific
- Takara Bio
Other Prominent Vendors
- Arbor Biotechnologies
- Beam Therapeutics
- Bluebird Bio
- Cellectis
- Caribou Biosciences
- Charles River Laboratories
- CRISPR Therapeutics
- HERA Biolabs
- Integrated DNA Technologies
- Lonza
- New England Biolabs
- OriGene Technologies
- Synthego
- Tecan
- PerkinElmer
- Precision BioSciences
- Intellia Therapeutics
- Pairwise
- Sangamo Therapeutics
- Recombinetics
- Synbio Technologies
Key Topics Covered:
1 Research Methodology
2 Research Objectives
3 Research Process
4 Scope & Coverage
5 Report Assumptions & Caveats
6 Market at a Glance
7 Premium Insights
8 Introduction
9 Market Opportunities & Trends
10 Market Growth Enablers
11 Market Restraints
12 Market Landscape
13 Product
14 Technology
15 Application
16 End-User
17 Competitive Landscape
18 Key Company Profiles
19 Other Prominent Vendors
20 Report Summary
21 Quantitative Summary
22 Appendix
Companies Mentioned
- Agilent Technologies
- Creative Biogene
- Genscript
- Merck KGaA
- Thermo Fisher Scientific
- Takara Bio
- Arbor Biotechnologies
- Beam Therapeutics
- Bluebird Bio
- Cellectis
- Caribou Biosciences
- Charles River Laboratories
- CRISPR Therapeutics
- HERA Biolabs
- Integrated DNA Technologies
- Lonza
- New England Biolabs
- OriGene Technologies
- Synthego
- Tecan
- PerkinElmer
- Precision BioSciences
- Intellia Therapeutics
- Pairwise
- Sangamo Therapeutics
- Recombinetics
- Synbio Technologies
For more information about this report visit https://www.researchandmarkets.com/r/v5kqjq
Attachment
